Treatment response scoring systems to assess long term prognosis in relapsing-remitting multiple sclerosis patients
ECTRIMS Online Library. Rio J. 09/13/19; 279564; 305
Jordi Rio
Jordi Rio
Contributions
Abstract

Abstract: 305

Type: Scientific Session

Abstract Category: Therapy - Tools for detecting therapeutic response

J. Rio1, A. Rovira2, C. Gasperini3, M. Tintoré1, L. Prosperini3, S. Otero-Romero1, M. Comabella1, À. Vidal-Jordana1, I. Galan1, L. Midaglia1, B. Rodríguez-Acevedo1, A. Zabalza1, J. Castilló1, G. Arrambide1, C. Nos1, C. Auger2, J. Sastre-Garriga1, X. Montalban1,4

1Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, 2MRI Unit-Dept. of Radiology, Vall Hebron University Hospital, Barcelona, Spain, 3Department of Neurosciences, S Camillo-Forlanini Hospital, Rome, Italy, 4Division of Neurology, Saint Michael's Hospital-University of Toronto, Toronto, ON, Canada

Objectives: The aim of this study is to compare different tretment response scoring systems to assess long term prognosis in treated RRMS patients.
Methods
: Consecutive RRMS treated patientsunderwent brain MRI before the onset of therapy with IFNband 12 months after, and a neurological assessment every 3 or 6 months. Clinical and demographic characteristics of patients were collected at baseline. Patients were classified based on the presence of active lesions (new T2 or gadolinium enhancement), presence of relapses and disability increase. Cox-Regresion and survival analysis were performed in order to identify scores predicting long-term disability defined as reaching an EDSS of 6 after 10 years of follow-up and time to reach an EDSS 6.
Results
: We included 319 RRMS patients. After the first year of treatment several scores systems (Rio score (RS), modfied Rio score (MRS), MAGNIMS score (MS) and ROAD score (RoS)) were calculated. Prediction model analysis showed that all scores were able to identify significantly patients with an EDSS of 6 after 10 years of follow-up. Survival analysis showed that patients with a RS > 1 and RoS > 3 had a significant probability of achieveing an EDSS of 6 while this probality was observed in patients with MRS and MS > 0. The score with the best sensitivity (85%) was the RoS, while the MRS showed the best specificity (88%). RS showed the best positive predictive value (42%), and RoS the best negative predictive value (94%). Finally, the RS demostrated the best accuracy (81%).
Conclusions
: In RRMS patients treated withIFNb,the combined clinical-radiological activity measures integrated into different scores during the first year of treatment have an acceptable prognostic value for identifying patients with long-term disability.
Disclosure: J Río has received speaking honoraria and personal compensation for participating on
Advisory Boards from Almirall, Bayer-Schering Healthcare, Biogen-Idec, Genzyme, Merck- Serono, Novartis, Teva, and Sanofi-Aventis.
A Rovira serves on scientific advisory boards for Novartis, Sanofi-Genzyme, Icometrix, SyntheticMR, Bayer, Biogen and OLEA Medical, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche and Biogen.
C Gasperini hasreceived fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme
M Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal- ETC
L Prosperini has received fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme
S Otero-Romero has received compensation for consulting services from Biogen-Idec and Genzyme, and research support from Novartis.
M Comabella has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis.
C Nos has received funding for travel from Biogen Idec and F. Hoffmann-La Roche, Ltd.and speaker honoraria from Novartis.
A Vidal-Jordana receives support for contracts Juan Rodes (JR16/00024) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain; and has received speaking honoraria and travel expenses from Novartis, Roche, Teva, Biogen and Sanofi-Genzyme
G. Arrambide has received compensation for consulting services or participation in advisory boards from Sanofi and Merck; research support from Novartis; travel expenses for scientific meetings from Novartis and Roche; and speaking honoraria from Stendhal, Sanofi and Merck.
Breogán Rodríguez-Acevedo has received honoraria for consulting services from Wellspect.
C Auger has received speaking honoraria from Novartis, Biogen and Stendhal.
J Sastre-Garriga has received compensation for participating on Advisory Boards,speaking honoraria and travel expenses for scientific meetings, consulting services orresearch support from Celgene, Novartis, Biogen, Teva, Merck, Almirall, and Genzyme.
X Montalban has received speaking honoraria and travel expenses for participation inscientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Actelion, Amirall, Bayer, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.
L Midaglia, I Galán, C Espejo, J Castilló, and AnaZabalza report no disclosures.

Abstract: 305

Type: Scientific Session

Abstract Category: Therapy - Tools for detecting therapeutic response

J. Rio1, A. Rovira2, C. Gasperini3, M. Tintoré1, L. Prosperini3, S. Otero-Romero1, M. Comabella1, À. Vidal-Jordana1, I. Galan1, L. Midaglia1, B. Rodríguez-Acevedo1, A. Zabalza1, J. Castilló1, G. Arrambide1, C. Nos1, C. Auger2, J. Sastre-Garriga1, X. Montalban1,4

1Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, 2MRI Unit-Dept. of Radiology, Vall Hebron University Hospital, Barcelona, Spain, 3Department of Neurosciences, S Camillo-Forlanini Hospital, Rome, Italy, 4Division of Neurology, Saint Michael's Hospital-University of Toronto, Toronto, ON, Canada

Objectives: The aim of this study is to compare different tretment response scoring systems to assess long term prognosis in treated RRMS patients.
Methods
: Consecutive RRMS treated patientsunderwent brain MRI before the onset of therapy with IFNband 12 months after, and a neurological assessment every 3 or 6 months. Clinical and demographic characteristics of patients were collected at baseline. Patients were classified based on the presence of active lesions (new T2 or gadolinium enhancement), presence of relapses and disability increase. Cox-Regresion and survival analysis were performed in order to identify scores predicting long-term disability defined as reaching an EDSS of 6 after 10 years of follow-up and time to reach an EDSS 6.
Results
: We included 319 RRMS patients. After the first year of treatment several scores systems (Rio score (RS), modfied Rio score (MRS), MAGNIMS score (MS) and ROAD score (RoS)) were calculated. Prediction model analysis showed that all scores were able to identify significantly patients with an EDSS of 6 after 10 years of follow-up. Survival analysis showed that patients with a RS > 1 and RoS > 3 had a significant probability of achieveing an EDSS of 6 while this probality was observed in patients with MRS and MS > 0. The score with the best sensitivity (85%) was the RoS, while the MRS showed the best specificity (88%). RS showed the best positive predictive value (42%), and RoS the best negative predictive value (94%). Finally, the RS demostrated the best accuracy (81%).
Conclusions
: In RRMS patients treated withIFNb,the combined clinical-radiological activity measures integrated into different scores during the first year of treatment have an acceptable prognostic value for identifying patients with long-term disability.
Disclosure: J Río has received speaking honoraria and personal compensation for participating on
Advisory Boards from Almirall, Bayer-Schering Healthcare, Biogen-Idec, Genzyme, Merck- Serono, Novartis, Teva, and Sanofi-Aventis.
A Rovira serves on scientific advisory boards for Novartis, Sanofi-Genzyme, Icometrix, SyntheticMR, Bayer, Biogen and OLEA Medical, and has received speaker honoraria from Bayer, Sanofi-Genzyme, Bracco, Merck-Serono, Teva Pharmaceutical Industries Ltd, Novartis, Roche and Biogen.
C Gasperini hasreceived fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme
M Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal- ETC
L Prosperini has received fee as speaker or advisory board by Merck, Bayer, Biogen, Novartis, Teva, Genzyme
S Otero-Romero has received compensation for consulting services from Biogen-Idec and Genzyme, and research support from Novartis.
M Comabella has received compensation for consulting services and speaking honoraria from Bayer Schering Pharma, Merk Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, and Novartis.
C Nos has received funding for travel from Biogen Idec and F. Hoffmann-La Roche, Ltd.and speaker honoraria from Novartis.
A Vidal-Jordana receives support for contracts Juan Rodes (JR16/00024) from Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain; and has received speaking honoraria and travel expenses from Novartis, Roche, Teva, Biogen and Sanofi-Genzyme
G. Arrambide has received compensation for consulting services or participation in advisory boards from Sanofi and Merck; research support from Novartis; travel expenses for scientific meetings from Novartis and Roche; and speaking honoraria from Stendhal, Sanofi and Merck.
Breogán Rodríguez-Acevedo has received honoraria for consulting services from Wellspect.
C Auger has received speaking honoraria from Novartis, Biogen and Stendhal.
J Sastre-Garriga has received compensation for participating on Advisory Boards,speaking honoraria and travel expenses for scientific meetings, consulting services orresearch support from Celgene, Novartis, Biogen, Teva, Merck, Almirall, and Genzyme.
X Montalban has received speaking honoraria and travel expenses for participation inscientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past with Actelion, Amirall, Bayer, Biogen, Celgene, Genzyme, Hoffmann-La Roche, Novartis, Oryzon Genomics, Sanofi-Genzyme and Teva Pharmaceutical.
L Midaglia, I Galán, C Espejo, J Castilló, and AnaZabalza report no disclosures.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies